“Adverse Events of Special Interest in Patients with Advanced Basal Cell Carcinoma Receiving Sonidegib: Long-Term 42-Month Results from the BOLT Study” (2020) SKIN The Journal of Cutaneous Medicine, 4(5), p. s67. doi:10.25251/skin.4.supp.66.